Yues International Holdings Group Limited
樂氏國際控股集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1529)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

References are made to the annual report of Yues International Holdings Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") for the year ended 31 December 2025 published on 29 April 2026 (the "**2025 Annual Report**") and the announcement of the Company dated 13 April 2026, in relation to, among other things, the change in use of proceeds from the Rights Issue (the "**Announcement**"). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the 2025 Annual Report.

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to provide supplemental information regarding the delay in utilising certain proceeds from the Rights Issue and a detailed breakdown of the proceeds from the 2023 Placing and the Rights Issue utilised for general working capital.

CLARIFICATION OF THE DISCLOSURE ON PAGE 25 OF THE 2025 ANNUAL REPORT

As disclosed in the notes to the table on page 25 of the 2025 Annual Report, the expected timetables for fully utilising the remaining net proceeds allocated to (a) general working capital; and (b) the development of the goat milk product business in the Inner Mongolia Autonomous Region were revised to on or before 31 December 2026. The original and revised expected utilisation timetables, together with the relevant amounts as at 31 December 2025, are set out below:

Intended use of net proceeds	Planned allocation *(HK$ million)*	Utilised as of 31 December 2025 *(HK$ million)*	Unutilised as of 31 December 2025 *(HK$ million)*	Original expected timetable	Revised expected timetable
General working capital	27.6	8.2	19.4	Within 12 months following completion of the Rights Issue (i.e. by around May 2026)	On or before 31 December 2026

Intended use of net proceeds	Planned allocation *(HK$ million)*	Utilised as of 31 December 2025 *(HK$ million)*	Unutilised as of 31 December 2025 *(HK$ million)*	Original expected timetable	Revised expected timetable
Development of the goat milk product business in the Inner Mongolia Autonomous Region	20.0	4.7	15.3	Research and development in the second half of 2025; development of marketing channels and sourcing of goat milk on or before December 2025	On or before 31 December 2026

Note:

(1) The original timetable for general working capital is presented by reference to the completion of the Rights Issue in May 2025.

(2) The intended use set out in the table above reflects the allocation and utilisation position as at 31 December 2025. The subsequent change in use of the unutilised balance originally allocated to the goat milk product business is described under the section headed "SUBSEQUENT CHANGE IN USE OF PROCEEDS FROM THE RIGHTS ISSUE" below.

Accordingly, as at 31 December 2025, the revised timetable represents a delay of approximately seven months for the remaining net proceeds allocated to general working capital and approximately one year for the remaining net proceeds allocated to the goat milk product business. As at 31 December 2025, save for the revised utilisation timetables described above, there had been no change in the intended use categories or allocation of the net proceeds from the Rights Issue.

Subsequent to 31 December 2025, as disclosed in the Announcement, the Board resolved on 13 April 2026 to broaden the permitted use of the unutilised balance originally allocated to the goat milk product business to the Group's broader big health business, including, among others, traditional Chinese medicine, goat milk and other health-related products.

REASONS FOR THE DELAYS

The slower-than-expected utilisation of the net proceeds allocated to general working capital was mainly attributable to the more challenging operating environment for the Group's logistics and warehousing businesses since the second half of 2025. The Group accordingly adopted cost-control measures and reduced its planned expenditure, resulting in lower-than-expected working capital requirements and a slower utilisation of the relevant proceeds.

The slower-than-expected utilisation of the net proceeds allocated to the development of the goat milk product business in the Inner Mongolia Autonomous Region was mainly attributable to changes in the regulatory and compliance environment applicable to goat milk products in Mainland China and weaker-than-expected demand in the market for goat milk powder products targeting middle-aged and elderly consumers. The Group therefore slowed the relevant research and development, marketing channel development and goat milk sourcing activities and reassessed the deployment of the remaining proceeds, the permitted use of which was subsequently broadened to the Group's big health business as disclosed in the Announcement.

Notwithstanding the subsequent change in use described below, the expected timetable for fully utilising the relevant balance remains on or before 31 December 2026. The revised expected timetables above represent the Board's best estimates based on the Group's current business plan and circumstances and may be subject to change in light of future business and market developments.

SUBSEQUENT CHANGE IN USE OF PROCEEDS FROM THE RIGHTS ISSUE

As disclosed in the Announcement, the Board resolved on 13 April 2026 to broaden the permitted use of the approximately HK$15.26 million unutilised proceeds originally allocated to the goat milk product business to the Group's broader big health business, including, among others, traditional Chinese medicine, goat milk and other health-related products. Such change was made to better align the use of proceeds with the Group's latest business development strategy, and the Company expects to fully utilise the relevant proceeds by 31 December 2026.

DETAILED BREAKDOWN OF PROCEEDS UTILISED FOR GENERAL WORKING CAPITAL

As disclosed in the 2025 Annual Report, HK$10.0 million of the net proceeds from the 2023 Placing was reallocated to general working capital, of which HK$4.8 million had been utilised and HK$5.2 million remained unutilised as of 31 December 2025. In addition, HK$8.2 million of the net proceeds from the Rights Issue had been utilised for general working capital as of 31 December 2025. A detailed breakdown of such utilisation is set out below:

Nature of general working capital expenditure	**2023 Placing** *(HK$ million)*	**Rights Issue** *(HK$ million)*
Purchase of inventories, being mainly traditional Chinese medicine related products	3.7	—
Directors' remuneration	—	4.3
Employee benefit expenses	0.8	0.6
Legal and professional fees	—	1.6
Rental and utility expenses	0.2	1.0
Printing expenses	—	0.4
Other operating expenses	0.1	0.3
Total	4.8	8.2

Note: All amounts are approximate and may not add up exactly due to rounding.

The above proceeds were applied towards the Group's ordinary operating and administrative requirements. The remaining unutilised proceeds will be applied in accordance with their respective intended uses and expected utilisation timetables as disclosed in the 2025 Annual Report, the Announcement and this announcement.

MEASURES TO PREVENT RECURRENCE

The Board has reviewed the matter and resolved to strengthen, with immediate effect, the Company's internal control procedures for monitoring and disclosing the use of proceeds. In particular, (i) the finance department will maintain and update, on a monthly basis, a dedicated register for each fund-raising exercise, recording the original allocation, actual utilisation, unutilised balance, expected utilisation timetable and the reasons for any actual or anticipated deviation, and reconcile such register against the Group's accounting records; (ii) the finance department and the company secretary will jointly review such register at least quarterly and before the preparation of each interim and annual report, and promptly escalate any material change or delay to the Board and the Audit Committee for assessment of the applicable disclosure requirements; and (iii) before the publication of each interim and annual report, the finance department will prepare, and the company secretary will review and sign off, a specific disclosure checklist covering the applicable requirements under the Listing Rules and the guidance set out in the Stock Exchange's Guide on Preparation of Annual Report, and the Company will seek advice from its external professional advisers where appropriate. The Company will also arrange periodic training for the relevant Directors and employees on the applicable disclosure requirements.

The supplemental information set out in this announcement does not affect any other information contained in the 2025 Annual Report. Save as disclosed in this announcement, all other information in the 2025 Annual Report remains unchanged. This announcement should be read in conjunction with the 2025 Annual Report.

By order of the Board
Yues International Holdings Group Limited
Le Kang
Chairman

Hong Kong, 10 September 2026

As at the date of this announcement, the Board consists of five executive Directors, Mr. Le Kang, Mr. Li Zhigang, Ms. Liu Ping, Mr. Yueh Chueh-Hsin and Mr. Xiao Wentao, and three independent non-executive Directors, Mr. Lau Wai Piu Patrick, Dr. Wang Yi and Mr. Zhang Yao.